UK markets open in 5 hours 37 minutes
  • NIKKEI 225

    26,251.27
    -172.20 (-0.65%)
     
  • HANG SENG

    21,853.07
    0.00 (0.00%)
     
  • CRUDE OIL

    101.31
    +1.81 (+1.82%)
     
  • GOLD FUTURES

    1,770.30
    +6.40 (+0.36%)
     
  • DOW

    30,967.82
    -129.44 (-0.42%)
     
  • BTC-GBP

    16,888.80
    -183.13 (-1.07%)
     
  • CMC Crypto 200

    437.30
    -2.73 (-0.62%)
     
  • ^IXIC

    11,322.24
    +194.39 (+1.75%)
     
  • ^FTAS

    3,863.91
    -103.70 (-2.61%)
     

Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Tiziana Life Sciences Plc
Tiziana Life Sciences Plc

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, purchased 18,000 common shares at $0.80 per share.

The acquisition takes Mr Cerrone's interests from 37.58% to 37.60%.

About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further inquiries:

Tiziana Life Sciences Ltd

Hana Malik, Business Development,
and Investor Relations Manager  
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting